Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
CCXI's Cash to Debt is ranked higher than
83% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. CCXI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CCXI' s Cash to Debt Range Over the Past 10 Years
Min: 6.43  Med: 836 Max: No Debt
Current: No Debt
Equity to Asset 0.41
CCXI's Equity to Asset is ranked lower than
78% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CCXI: 0.41 )
Ranked among companies with meaningful Equity to Asset only.
CCXI' s Equity to Asset Range Over the Past 10 Years
Min: 0.41  Med: 0.9 Max: 0.96
Current: 0.41
0.41
0.96
Interest Coverage No Debt
CCXI's Interest Coverage is ranked higher than
80% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CCXI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CCXI' s Interest Coverage Range Over the Past 10 Years
Min: 206.51  Med: 5103.26 Max: No Debt
Current: No Debt
F-Score: 4
Z-Score: -0.75
M-Score: 1.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -631.05
CCXI's Operating margin (%) is ranked lower than
73% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. CCXI: -631.05 )
Ranked among companies with meaningful Operating margin (%) only.
CCXI' s Operating margin (%) Range Over the Past 10 Years
Min: -731.32  Med: -17.09 Max: 31.55
Current: -631.05
-731.32
31.55
Net-margin (%) -622.65
CCXI's Net-margin (%) is ranked lower than
73% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. CCXI: -622.65 )
Ranked among companies with meaningful Net-margin (%) only.
CCXI' s Net-margin (%) Range Over the Past 10 Years
Min: -736.13  Med: -14.58 Max: 31.41
Current: -622.65
-736.13
31.41
ROE (%) -66.93
CCXI's ROE (%) is ranked lower than
69% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. CCXI: -66.93 )
Ranked among companies with meaningful ROE (%) only.
CCXI' s ROE (%) Range Over the Past 10 Years
Min: -66.93  Med: -30.25 Max: 20.21
Current: -66.93
-66.93
20.21
ROA (%) -43.12
CCXI's ROA (%) is ranked lower than
61% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. CCXI: -43.12 )
Ranked among companies with meaningful ROA (%) only.
CCXI' s ROA (%) Range Over the Past 10 Years
Min: -48.48  Med: -28.15 Max: 15.1
Current: -43.12
-48.48
15.1
ROC (Joel Greenblatt) (%) -4917.50
CCXI's ROC (Joel Greenblatt) (%) is ranked lower than
80% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. CCXI: -4917.50 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CCXI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4917.5  Med: -2639.91 Max: 66.57
Current: -4917.5
-4917.5
66.57
Revenue Growth (3Y)(%) -100.00
CCXI's Revenue Growth (3Y)(%) is ranked lower than
99% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. CCXI: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CCXI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -100 Max: -50.7
Current: -100
EBITDA Growth (3Y)(%) -0.30
CCXI's EBITDA Growth (3Y)(%) is ranked lower than
51% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. CCXI: -0.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CCXI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 60.4 Max: 129.2
Current: -0.3
0
129.2
EPS Growth (3Y)(%) -1.50
CCXI's EPS Growth (3Y)(%) is ranked higher than
52% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. CCXI: -1.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CCXI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -0.75 Max: 105.2
Current: -1.5
0
105.2
GuruFocus has detected 3 Warning Signs with ChemoCentryx Inc $CCXI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CCXI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CCXI Guru Trades in Q1 2016

Jim Simons 169,054 sh (+281.61%)
Steven Cohen Sold Out
Chuck Royce 32,900 sh (-1.20%)
» More
Q2 2016

CCXI Guru Trades in Q2 2016

Chuck Royce Sold Out
Jim Simons 69,681 sh (-58.78%)
» More
Q3 2016

CCXI Guru Trades in Q3 2016

Jim Simons 197,981 sh (+184.12%)
» More
Q4 2016

CCXI Guru Trades in Q4 2016

Jim Simons 470,581 sh (+137.69%)
» More
» Details

Insider Trades

Latest Guru Trades with CCXI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 2834
Compare:OTCPK:PTCHF, NAS:VYGR, AMEX:BTX, NAS:NERV, NAS:LJPC, NAS:OMED, NAS:SVA, NAS:ARNA, NAS:GERN, NAS:BOLD, NAS:PRTK, NAS:ADXS, OTCPK:RCAR, NAS:BLCM, NAS:BSTC, NAS:FOMX, NAS:PDLI, NAS:CRIS, NAS:EDGE, NAS:ADAP » details
Traded in other countries:2CX.Germany,
Chemocentryx Inc is a biopharmaceutical company engaged in discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer.

Chemocentryx Inc was incorporated in the state of Delaware on November 8, 1996. The Company is a biopharmaceutical company engaged in discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. It currently has five drug candidates in clinical development. CCX168 —Targeting the chemoattractant receptor known as C5aR, CCX168 has successfully completed and reported positive clinical data from the first two steps of a three-step Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody, or ANCA, associated renal vasculitis, or AARV. CCX140 — Targeting the chemokine receptor known as CCR2, CCX140 is currently in Phase II clinical development in patients with diabetic nephropathy, a form of kidney disease. Vercirnon (also known as Traficet-EN, or CCX282) —Targeting the chemokine receptor known as CCR9, vercirnon is its drug candidate for the treatment of patients with moderate-to-severe Crohn's disease. CCX872 — its second generation orally administered inhibitor targeting CCR2, CCX872 is expected to complete Phase I clinical development. CCX507 — its second generation CCR9 inhibitor for the treatment of inflammatory bowel disease, or IBD, CCX507 is expected to complete Phase I clinical development. Its current drug candidates are manufactured using common chemical engineering and synthetic processes from readily available raw materials. It rely on contract manufacturing organizations to produce its drug candidates in accordance with the FDA's current good manufacturing practices, or cGMP, regulations for use in its clinical trials. The Company competes in the pharmaceutical, biotechnology and other related markets that address AARV, chronic kidney disease and diabetic nephropathy, IBD, rheumatoid arthritis, other autoimmune diseases and inflammatory disorders, and cancer. The Company competes with the pharmaceutical companies that currently sell or are developing drugs include AbbVie, Amgen, AstraZeneca, Biogen Idec, Bayer, Bristol-Myers Squibb, Elan, Roche/Genentech, GSK, Johnson & Johnson, Merck, Merck Serono, Takeda, Novartis, Pfizer, Sanofi and Teva. The Company and its manufacturers are subject to federal, state and local and foreign laws and regulations governing the use, generation, manufacture, storage, handling and disposal of these hazardous materials.

Ratios

vs
industry
vs
history
Price/Owner Earnings (ttm) 11.41
CCXI's Price/Owner Earnings (ttm) is ranked higher than
78% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 29.18 vs. CCXI: 11.41 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
CCXI' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 6.84  Med: 9.91 Max: 14.59
Current: 11.41
6.84
14.59
P/B 6.19
CCXI's P/B is ranked lower than
73% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. CCXI: 6.19 )
Ranked among companies with meaningful P/B only.
CCXI' s P/B Range Over the Past 10 Years
Min: 0.74  Med: 2.86 Max: 7.92
Current: 6.19
0.74
7.92
P/S 46.93
CCXI's P/S is ranked lower than
74% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. CCXI: 46.93 )
Ranked among companies with meaningful P/S only.
CCXI' s P/S Range Over the Past 10 Years
Min: 11.76  Med: 74.23 Max: 519.44
Current: 46.93
11.76
519.44
PFCF 8.46
CCXI's PFCF is ranked higher than
86% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. CCXI: 8.46 )
Ranked among companies with meaningful PFCF only.
CCXI' s PFCF Range Over the Past 10 Years
Min: 5.07  Med: 7.35 Max: 10.82
Current: 8.46
5.07
10.82
POCF 8.44
CCXI's POCF is ranked higher than
87% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 21.56 vs. CCXI: 8.44 )
Ranked among companies with meaningful POCF only.
CCXI' s POCF Range Over the Past 10 Years
Min: 5.06  Med: 7.33 Max: 10.79
Current: 8.44
5.06
10.79
Current Ratio 4.68
CCXI's Current Ratio is ranked higher than
54% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CCXI: 4.68 )
Ranked among companies with meaningful Current Ratio only.
CCXI' s Current Ratio Range Over the Past 10 Years
Min: 4.68  Med: 10.59 Max: 19.54
Current: 4.68
4.68
19.54
Quick Ratio 4.68
CCXI's Quick Ratio is ranked higher than
55% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. CCXI: 4.68 )
Ranked among companies with meaningful Quick Ratio only.
CCXI' s Quick Ratio Range Over the Past 10 Years
Min: 4.68  Med: 10.59 Max: 19.54
Current: 4.68
4.68
19.54
Days Sales Outstanding 6.22
CCXI's Days Sales Outstanding is ranked higher than
90% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. CCXI: 6.22 )
Ranked among companies with meaningful Days Sales Outstanding only.
CCXI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.84  Med: 77.86 Max: 260.05
Current: 6.22
5.84
260.05

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.70
CCXI's 3-Year Average Share Buyback Ratio is ranked higher than
64% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. CCXI: -6.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CCXI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -15  Med: -6.95 Max: 0
Current: -6.7
-15
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.00
CCXI's Price/Net Cash is ranked lower than
63% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: 5.89 vs. CCXI: 8.00 )
Ranked among companies with meaningful Price/Net Cash only.
CCXI' s Price/Net Cash Range Over the Past 10 Years
Min: 1.95  Med: 4.38 Max: 8
Current: 8
1.95
8
Price/Net Current Asset Value 7.74
CCXI's Price/Net Current Asset Value is ranked lower than
64% of the 879 Companies
in the Global Biotechnology industry.

( Industry Median: 5.57 vs. CCXI: 7.74 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CCXI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.92  Med: 4.31 Max: 7.74
Current: 7.74
1.92
7.74
Price/Tangible Book 6.18
CCXI's Price/Tangible Book is ranked lower than
65% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. CCXI: 6.18 )
Ranked among companies with meaningful Price/Tangible Book only.
CCXI' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.56  Med: 3.31 Max: 6.19
Current: 6.18
1.56
6.19
Price/Median PS Value 0.63
CCXI's Price/Median PS Value is ranked higher than
76% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. CCXI: 0.63 )
Ranked among companies with meaningful Price/Median PS Value only.
CCXI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.17  Med: 0.89 Max: 3.36
Current: 0.63
0.17
3.36
Earnings Yield (Greenblatt) (%) -20.70
CCXI's Earnings Yield (Greenblatt) (%) is ranked lower than
69% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. CCXI: -20.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CCXI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -257.62  Med: 0 Max: 0
Current: -20.7
-257.62
0

More Statistics

Revenue (TTM) (Mil) $7.05
EPS (TTM) $ -0.97
Beta2.05
Short Percentage of Float9.42%
52-Week Range $1.92 - 9.10
Shares Outstanding (Mil)47.81
» More Articles for CCXI

Headlines

Articles On GuruFocus.com
Immune Design Insider Buys Shares Oct 03 2016 
Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 

More From Other Websites
CHEMOCENTRYX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Feb 14 2017
Vifor Pharma and ChemoCentryx Announce Expansion of Avacopan Agreement for Rare Renal Diseases Feb 14 2017
ChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor... Jan 20 2017
ChemoCentryx, Inc. (Nasdaq: CCXI) to Ring The Nasdaq Stock Market Closing Bell Remotely from the... Jan 20 2017
ChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : January 19,... Jan 19 2017
ChemoCentryx Provides Corporate Update Including Development Strategy for Lead Programs in Rare... Jan 09 2017
ChemoCentryx to Present at the 35th Annual J.P. Morgan Healthcare Conference Jan 04 2017
ChemoCentryx, Inc. – Value Analysis (NASDAQ:CCXI) : January 3, 2017 Jan 03 2017
ChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : January 2,... Jan 02 2017
Vifor Pharma and ChemoCentryx announce expansion of Kidney Health Alliance to include CCX140 to... Dec 23 2016
ChemoCentryx Expands Partnership With Vifor Pharma, Licenses CCX140 For Renal Diseases Dec 22 2016
CHEMOCENTRYX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Dec 22 2016
Vifor Pharma and ChemoCentryx Announce Expansion of Kidney Health Alliance to Include CCX140 to... Dec 22 2016
Is ChemoCentryx Inc (CCXI) A Stock Worth Buying? Dec 16 2016
Everyday Health Inc (EVDY), ANSYS, Inc. (ANSS), More: Why You Should Pay Attention To These Stocks Nov 16 2016
CHEMOCENTRYX, INC. Financials Nov 16 2016
CHEMOCENTRYX, INC. Files SEC form 10-Q, Quarterly Report Nov 08 2016
Edited Transcript of CCXI earnings conference call or presentation 7-Nov-16 10:00pm GMT Nov 08 2016
CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 07 2016
ChemoCentryx to Hold Third Quarter 2016 Financial Results Conference Call on Monday, November 7,... Nov 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)